Skip to main content
Premium Trial:

Request an Annual Quote

Cepheid s Q1 Revenues More Than Double, Losses Narrow

NEW YORK, May 5 (GenomeWeb News) - Cepheid yesterday reported more than doubled revenues for the first quarter of 2005, while the company's net loss narrowed.


Revenues for the quarter increased to $19.6 million from $7.3 million during the same quarter last year. Most of this boost resulted from increased sales of reagents and disposables, Cepheid said.


Research and development costs climbed to $4.5 million from $3.6 million during the same period a year ago.


Cepheid's net loss narrowed to $3.5 million, or $.08 per share, from $4.1 million, or $.11 per share, during the year-ago period.


As of March 31, Cepheid had $21.4 million in cash and cash equivalents, and $33.5 million in marketable securities.

The Scan

Germline-Targeting HIV Vaccine Shows Promise in Phase I Trial

A National Institutes of Health-led team reports in Science that a broadly neutralizing antibody HIV vaccine induced bnAb precursors in 97 percent of those given the vaccine.

Study Uncovers Genetic Mutation in Childhood Glaucoma

A study in the Journal of Clinical Investigation ties a heterozygous missense variant in thrombospondin 1 to childhood glaucoma.

Gene Co-Expression Database for Humans, Model Organisms Gets Update

GeneFriends has been updated to include gene and transcript co-expression networks based on RNA-seq data from 46,475 human and 34,322 mouse samples, a new paper in Nucleic Acids Research says.

New Study Investigates Genomics of Fanconi Anemia Repair Pathway in Cancer

A Rockefeller University team reports in Nature that FA repair deficiency leads to structural variants that can contribute to genomic instability.